How to Vet a Bioidentical Hormone Therapy Clinic for Women

Why Vetting a BHRT Clinic Matters

Hormone therapy decisions carry real clinical consequences. The quality of care at BHRT clinics varies enormously, from academic medical centers with menopause fellowship-trained physicians to wellness spas staffed by unlicensed "hormone coaches."

The North American Menopause Society (NAMS) position statement, last updated in 2022, specifies that hormone therapy for menopausal symptoms should be individualized and supervised by a qualified clinician who reviews personal and family medical history, symptom severity, and cardiovascular risk before any prescription is written. [1] Skipping that process is not a minor shortcut. It is the difference between evidence-based care and a protocol that may expose you to unmonitored risks.

The sections below give you a structured checklist you can bring to any first appointment or phone consultation.

Step 1: Verify Physician Credentials and Specialty Training

The first and most consequential check is who will actually be prescribing. A legitimate BHRT clinic is physician-led, not nurse-coach-led, for the prescribing function.

Board Certification to Look For

The physician should hold active certification through an ABMS-recognized board. Relevant boards include:

• American Board of Obstetrics and Gynecology (ABOG)
• American Board of Internal Medicine (ABIM)
• American Board of Family Medicine (ABFM)
• American Board of Endocrinology, Diabetes, and Metabolism

You can verify any physician's board certification for free at certificationmatters.org or through the ABMS member board portals.

The NAMS Certified Menopause Practitioner Credential

The gold-standard specialty credential for menopause care is the NAMS Certified Menopause Practitioner (NCMP) designation. NCMP holders must pass a written examination covering evidence-based menopause management and renew every three years. NAMS maintains a public provider finder at menopause.org. [2]

Nurse practitioners and physician assistants can provide excellent hormone care, but in a BHRT clinic, the prescribing authority and liability must trace back to a licensed MD or DO who has reviewed your case, not just co-signed a template.

What to Ask Directly

Call the clinic and ask: "Which physician will supervise my care, what board are they certified by, and do they hold an NCMP or equivalent menopause credential?" A clinic that cannot answer that question within 24 hours warrants serious hesitation.

Step 2: Evaluate the Diagnostic Protocol Before Prescribing

A credible clinic does not guess at your hormone levels. It measures them, interprets them in clinical context, and re-checks them after any dose change.

Minimum Baseline Lab Panel

Before any BHRT prescription is written, expect a clinic to order serum (blood) testing that includes at minimum:

• FSH and LH (to confirm menopausal or perimenopausal status)
• Estradiol (E2)
• Progesterone
• Total and free testosterone
• Sex hormone-binding globulin (SHBG)
• Thyroid-stimulating hormone (TSH) (thyroid dysfunction mimics many menopause symptoms)
• Complete metabolic panel (CMP) and lipid panel (cardiovascular baseline)

Salivary or dried urine hormone testing is still marketed widely, but it is not validated for clinical dosing decisions. The Endocrine Society's clinical practice guidelines recommend serum testing as the standard method for evaluating sex steroid levels in women. [3] A clinic insisting that saliva testing is superior to serum is a significant yellow flag.

Symptom Questionnaires Are Supplementary, Not Sufficient

The Menopause Rating Scale (MRS) and Greene Climacteric Scale are validated instruments that help quantify vasomotor, psychological, and urogenital symptoms. They belong in a good intake process. They do not replace lab testing, a physical exam, or a personal cancer history review.

Follow-Up Testing Schedule

Dose adjustments without confirmatory labs are guesswork. After initiation, a responsible clinic reschedules labs at 6 to 12 weeks, then monitors annually at minimum. If a clinic advertises "set it and forget it" dosing, that is a problem, not a feature.

Step 3: Understand FDA-Approved Bioidentical Versus Custom-Compounded Products

This distinction confuses many patients and some clinicians. Both categories can carry the word "bioidentical," but their regulatory status differs dramatically.

FDA-Approved Bioidentical Hormones

Several bioidentical hormone products are FDA-approved and have undergone clinical trials for efficacy and safety:

• Estradiol transdermal patches: Vivelle-Dot, Climara, Alora
• Estradiol gel: EstroGel, Divigel
• Estradiol vaginal ring: Estring, Femring
• Oral micronized progesterone: Prometrium 100 mg and 200 mg
• Oral estradiol: Estrace

The FDA approval process requires manufacturers to demonstrate consistent potency, purity, and manufacturing-site inspections. Safety labeling reflects data from actual clinical trials.

Custom-Compounded BHRT

Compounding pharmacies can create hormone preparations in doses, delivery vehicles, or hormone combinations not available commercially, such as a biest cream (estriol plus estradiol) or a vaginal DHEA suppository at a non-standard dose. These preparations serve genuine clinical needs for some patients, particularly those with allergies to commercial excipients.

The FDA has stated explicitly that it has not approved any compounded hormone therapy for safety or efficacy, and that the risks of compounded products are not well characterized. [4] The American College of Obstetricians and Gynecologists (ACOG) echoes this: "Custom-compounded hormones should not be recommended over FDA-approved menopausal hormone therapy." [5]

A clinic using compounded products is not automatically illegitimate. But it should be explaining that distinction clearly, using a PCAB-accredited compounding pharmacy, and defaulting to FDA-approved products whenever a commercial equivalent exists.

Questions to Ask About Compounding

Ask the clinic:

1. Which pharmacy compounds your prescriptions?
2. Is that pharmacy PCAB-accredited or USP 795/797 compliant?
3. Does the pharmacy provide certificates of analysis (COA) confirming potency and sterility for each batch?

If the clinic cannot name the pharmacy or supply COA documentation on request, do not proceed.

Step 4: Assess How the Clinic Handles Risk Stratification

Hormone therapy is not appropriate for all women. A clinic that prescribes to every patient without exception is not doing individualized medicine.

Absolute and Relative Contraindications

Per NAMS 2022 guidelines and the ACOG Practice Bulletin on Hormone Therapy in Primary Ovarian Insufficiency, absolute contraindications to systemic estrogen include: [1, 6]

• Personal history of estrogen receptor-positive (ER+) breast cancer
• Active or recent coronary artery disease
• History of venous thromboembolism (VTE) or stroke
• Active liver disease
• Unexplained vaginal bleeding

Women over age 60 or more than 10 years past their final menstrual period may face a less favorable cardiovascular risk-benefit ratio, and that calculation should be documented.

The CROWN Study Timing Hypothesis Context

The Women's Health Initiative (WHI, N=16,608 in the combined estrogen-progestin arm) found elevated breast cancer risk with conjugated equine estrogen plus medroxyprogesterone acetate. [7] However, that trial enrolled women with a mean age of 63, an average of 12 years past menopause, and used oral CEE plus synthetic MPA, not transdermal bioidentical estradiol plus micronized progesterone.

The E3N cohort study (N=80,377 French women) found that transdermal estradiol combined with micronized progesterone was associated with no statistically significant increase in breast cancer risk over a mean follow-up of 8.1 years (relative risk 1.00, 95% CI 0.83 to 1.22), while oral estrogen with synthetic progestins carried higher risk. [8] A clinic that cites WHI as universal proof that all HRT is equally dangerous is misrepresenting the literature. So is a clinic that says BHRT carries zero breast cancer risk. The honest answer lives in the nuance between those extremes.

What a Good Risk Discussion Looks Like

Before prescribing, a responsible provider should document:

• Personal and first-degree family history of breast, ovarian, and uterine cancer
• Cardiovascular risk score (Framingham or ASCVD calculator output)
• Thrombotic risk (personal or family VTE history, Factor V Leiden screening if indicated)
• Bone density (DEXA scan) for women at fracture risk

If the clinic's intake form does not ask these questions, its risk stratification is incomplete.

Step 5: Review Informed Consent and Transparency Practices

Informed consent is both an ethical obligation and a legal requirement. Any clinic prescribing hormone therapy without written informed consent is operating below standard of care.

What the Consent Document Should Include

A proper BHRT informed consent document covers:

• Known risks of systemic estrogen therapy including VTE, stroke, and the still-debated breast cancer signal
• The distinction between FDA-approved and compounded products
• The fact that compounded products have not been individually tested for efficacy or safety
• Monitoring requirements and what happens if you miss follow-up labs
• Your right to discontinue therapy at any time

Price Transparency

A legitimate clinic gives you an itemized cost breakdown before you commit. This includes the initial consultation fee, lab costs (and whether your insurance is accepted for labs), ongoing prescription pricing, and the cost of follow-up visits. Telehealth BHRT subscriptions that bundle labs and prescriptions into a monthly fee are not automatically problematic, but you should understand exactly what you are paying for.

Step 6: Watch for These Specific Red Flags

The following list distills the most commonly observed practice patterns that distinguish substandard BHRT clinics from credible ones. Review this before your first appointment.

Red Flags That Indicate a Clinic May Not Be Safe

Testing and diagnosis red flags:

• Relies solely on symptom questionnaires or saliva/dried urine panels to prescribe
• No physician review of your personal cancer or cardiovascular history before prescribing
• No baseline serum labs required
• Offers a prescription after a 10-minute intake call with no clinician involvement

Product and pharmacy red flags:

• Cannot name the compounding pharmacy they use
• Promotes "estriol-only" therapy as cancer-proof (estriol has not been approved by the FDA for any indication, and the claim of cancer protection has no large RCT support)
• Sells hormone products directly through the clinic without a separate pharmacy license
• Claims compounded BHRT is "FDA-tested" or "FDA-certified" (it is not)

Clinical claims red flags:

• Guarantees "no side effects" or "100% natural means 100% safe"
• Claims that BHRT reverses aging, prevents Alzheimer's, or produces 20-year-old hormone levels as a stated treatment goal
• Dismisses the WHI entirely without acknowledging its methodological context
• Will not provide a written consent document before prescribing

Follow-up and monitoring red flags:

• No scheduled follow-up labs after dose initiation
• Refuses to coordinate care with your primary care physician or OB-GYN
• Does not have a clear escalation path if you experience a serious adverse event

Step 7: Evaluate the Telehealth BHRT Model Specifically

Many women now access BHRT through telehealth platforms, which can expand access to qualified menopause clinicians while removing geographic barriers. Telehealth BHRT is not inherently less safe than in-person care, but it requires the same vetting criteria applied with equal rigor.

What a Legitimate Telehealth BHRT Platform Does

A properly run telehealth BHRT service:

• Requires a synchronous video consultation (not just a text or async form) with a licensed prescribing clinician
• Orders baseline serum labs at a local draw site before prescribing, not after
• Uses FDA-approved products as first-line and clearly explains when and why it uses compounded alternatives
• Partners with PCAB-accredited compounding pharmacies for any custom formulations
• Schedules follow-up labs at 6 to 12 weeks and annually thereafter
• Has a 24-hour clinical escalation line or clear instructions for emergency situations

Questions to Ask a Telehealth Platform

Before signing up, ask:

1. Who are the prescribing clinicians, and what are their board certifications?
2. Do you default to FDA-approved bioidentical products or primarily to compounded preparations?
3. Which labs do you partner with, and does my insurance cover the draw?
4. What is your protocol if I experience a suspected adverse event outside business hours?
5. Will you share my records with my primary care physician if I request it?

A platform that deflects these questions or buries the answers in marketing language deserves skepticism.

Step 8: Cross-Check the Clinic Against Professional Society Databases

Use these free public resources to verify credentials and find vetted providers:

• NAMS Menopause Practitioner Directory: menopause.org/for-women/find-a-nams-menopause-practitioner [2]
• ABMS Board Certification Verification: certificationmatters.org
• State Medical Board License Lookup: available through the Federation of State Medical Boards at fsmb.org
• PCAB Pharmacy Accreditation Directory: pcab.org (for verifying the compounding pharmacy your clinic uses)
• FDA MedWatch: fda.gov/safety/medwatch for any adverse event reports filed against a specific compounding pharmacy [4]

Cross-referencing a clinic's physician roster against these databases takes under 10 minutes and provides objective verification independent of the clinic's own marketing.

Putting the Checklist Together

A single clinic visit or telehealth intake session rarely gives you all of the information above spontaneously. You need to ask. A physician or clinical team confident in their protocols will welcome specific questions about credentials, lab panels, compounding pharmacy accreditation, and consent documentation.

The Endocrine Society's 2015 clinical practice guideline on androgen therapy in women and the NAMS 2022 position statement both emphasize that hormone therapy decisions should be individualized, documented, and monitored, not standardized into a one-size subscription model. [1, 3]

Women who ask informed questions before committing to a clinic are far more likely to receive care that is appropriately tailored to their baseline health status, risk profile, and symptom severity. At HealthRX, every new patient undergoes a mandatory serum panel review and a synchronous clinical consultation before any prescription is generated. The 6-week follow-up lab recheck is built into the care protocol, not optional.